UA72783C2 - Agonist of central canabinoid receptors for preparation of drug disaccustoming smoking, combined pharmaceutical composition and kit - Google Patents

Agonist of central canabinoid receptors for preparation of drug disaccustoming smoking, combined pharmaceutical composition and kit Download PDF

Info

Publication number
UA72783C2
UA72783C2 UA2002075476A UA2002075476A UA72783C2 UA 72783 C2 UA72783 C2 UA 72783C2 UA 2002075476 A UA2002075476 A UA 2002075476A UA 2002075476 A UA2002075476 A UA 2002075476A UA 72783 C2 UA72783 C2 UA 72783C2
Authority
UA
Ukraine
Prior art keywords
solvates
acceptable salts
dichlorophenyl
carboxamide
chlorophenyl
Prior art date
Application number
UA2002075476A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UA72783C2 publication Critical patent/UA72783C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UA2002075476A 2000-02-09 2001-07-02 Agonist of central canabinoid receptors for preparation of drug disaccustoming smoking, combined pharmaceutical composition and kit UA72783C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0001682A FR2804604B1 (fr) 2000-02-09 2000-02-09 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
PCT/FR2001/000356 WO2001058450A2 (fr) 2000-02-09 2001-02-07 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Publications (1)

Publication Number Publication Date
UA72783C2 true UA72783C2 (en) 2005-04-15

Family

ID=8846875

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2002075476A UA72783C2 (en) 2000-02-09 2001-07-02 Agonist of central canabinoid receptors for preparation of drug disaccustoming smoking, combined pharmaceutical composition and kit

Country Status (32)

Country Link
US (2) US6930122B2 (de)
EP (1) EP1257275B1 (de)
JP (2) JP2003522145A (de)
CN (1) CN1250220C (de)
AR (1) AR028505A1 (de)
AT (1) ATE292467T1 (de)
AU (1) AU781827B2 (de)
BG (2) BG110386A (de)
BR (1) BR0108126A (de)
CA (1) CA2397262C (de)
CZ (1) CZ296685B6 (de)
DE (1) DE60109903T2 (de)
DK (1) DK1257275T3 (de)
EE (1) EE04836B1 (de)
ES (1) ES2240416T3 (de)
FR (1) FR2804604B1 (de)
HU (1) HU225328B1 (de)
IL (1) IL150710A0 (de)
IS (1) IS6450A (de)
MX (1) MXPA02007766A (de)
NO (1) NO324521B1 (de)
NZ (1) NZ519924A (de)
PL (1) PL201685B1 (de)
PT (1) PT1257275E (de)
RS (1) RS50404B (de)
RU (1) RU2257207C2 (de)
SI (1) SI1257275T1 (de)
SK (1) SK284952B6 (de)
TW (1) TWI243677B (de)
UA (1) UA72783C2 (de)
WO (1) WO2001058450A2 (de)
ZA (1) ZA200205317B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
CN1568432A (zh) 2001-08-13 2005-01-19 霍尼韦尔国际公司 使用沟槽为晶片承载的半导体器件提供电流控制
WO2003075917A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
JP2005528366A (ja) 2002-03-26 2005-09-22 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体モジュレータとしてのスピロ環式アミド
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
EP1499306A4 (de) 2002-04-12 2007-03-28 Merck & Co Inc Bicyclische amide
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
ES2294330T3 (es) 2002-08-02 2008-04-01 MERCK & CO., INC. Derivados de furo(2,3-b)piridina sustituidos.
JP2006510597A (ja) 2002-09-27 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 置換ピリミジン類
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
AU2003300967B2 (en) 2002-12-19 2009-05-28 Merck Sharp & Dohme Corp. Substituted amides
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
ATE496901T1 (de) * 2003-05-20 2011-02-15 Univ Tennessee Res Foundation Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2005044785A1 (en) * 2003-10-30 2005-05-19 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
CN101014605A (zh) 2004-07-12 2007-08-08 卡地拉健康护理有限公司 用作大麻素受体调节物的三环吡唑衍生物
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
CN101115726A (zh) 2004-12-03 2008-01-30 先灵公司 作为cb1拮抗剂的取代哌嗪
US7897601B2 (en) * 2006-01-18 2011-03-01 Intervet, Inc. Cannabinoid receptor modulators
CN101062919B (zh) * 2006-04-26 2012-08-15 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
WO2007121687A1 (en) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
WO2008046905A1 (en) * 2006-10-20 2008-04-24 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
WO2009005671A2 (en) * 2007-06-28 2009-01-08 Schering Corporation Substituted piperazines as cb1 antagonists
EP2548874A3 (de) * 2007-06-28 2013-05-15 Intervet International B.V. Substituierte Piperazine als CB1-Antagonisten
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
RU2533224C2 (ru) * 2010-07-21 2014-11-20 Мапикс Эс.Эй.Ар.Эл. Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2014181357A1 (en) * 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Novel pyrazole derivatives with silicon incorporation
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Also Published As

Publication number Publication date
BG110386A (en) 2009-09-30
HUP0300237A2 (hu) 2003-07-28
NZ519924A (en) 2005-01-28
US20030087933A1 (en) 2003-05-08
WO2001058450A2 (fr) 2001-08-16
JP2010018622A (ja) 2010-01-28
US6930122B2 (en) 2005-08-16
DE60109903T2 (de) 2006-02-09
AU781827B2 (en) 2005-06-16
FR2804604A1 (fr) 2001-08-10
HU225328B1 (en) 2006-09-28
CA2397262A1 (en) 2001-08-16
EE04836B1 (et) 2007-06-15
ZA200205317B (en) 2003-09-04
SK284952B6 (sk) 2006-03-02
BG106946A (bg) 2003-05-30
SK11292002A3 (sk) 2003-02-04
ATE292467T1 (de) 2005-04-15
SI1257275T1 (en) 2005-10-31
BG65856B1 (bg) 2010-03-31
IL150710A0 (en) 2003-02-12
RU2002118309A (ru) 2004-02-20
EE200200439A (et) 2003-12-15
CZ20022698A3 (cs) 2002-11-13
CN1406128A (zh) 2003-03-26
AR028505A1 (es) 2003-05-14
IS6450A (is) 2002-06-28
HUP0300237A3 (en) 2003-09-29
CZ296685B6 (cs) 2006-05-17
NO20023765L (no) 2002-10-09
DK1257275T3 (da) 2005-08-08
MXPA02007766A (es) 2002-10-11
ES2240416T3 (es) 2005-10-16
AU3562001A (en) 2001-08-20
YU59002A (sh) 2005-07-19
TWI243677B (en) 2005-11-21
HK1051140A1 (en) 2003-07-25
NO20023765D0 (no) 2002-08-08
EP1257275B1 (de) 2005-04-06
PL358221A1 (en) 2004-08-09
FR2804604B1 (fr) 2005-05-27
JP2003522145A (ja) 2003-07-22
NO324521B1 (no) 2007-11-12
EP1257275A2 (de) 2002-11-20
RS50404B (sr) 2009-12-31
PT1257275E (pt) 2005-07-29
RU2257207C2 (ru) 2005-07-27
WO2001058450A3 (fr) 2002-04-25
US20050187253A1 (en) 2005-08-25
CN1250220C (zh) 2006-04-12
DE60109903D1 (de) 2005-05-12
CA2397262C (en) 2007-09-11
PL201685B1 (pl) 2009-04-30
BR0108126A (pt) 2003-01-28

Similar Documents

Publication Publication Date Title
UA72783C2 (en) Agonist of central canabinoid receptors for preparation of drug disaccustoming smoking, combined pharmaceutical composition and kit
JP4925074B2 (ja) ミルタザピンと１種以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物
RS59002B1 (sr) Pirimido[4,5-b]indol derivati i njihova primena u ekspanziji hematopoetskih matičnih ćelija
US20070197544A1 (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
JP2005504113A (ja) Ｐｄｅ−ｖ阻害剤および他薬剤の医薬組合わせ
JP2007518755A (ja) モノアミン神経伝達物質再取り込み阻害剤及びｎ−メチル−ｄ−アスパラギン酸（ｎｍｄａ）受容体アンタゴニストを含む医薬組成物
JP4542777B2 (ja) 肺高血圧症を予防または治療するのに用いられる医薬の製造のためのイルベサルタンの使用
JP5925862B2 (ja) セロトニン受容体介在状態を治療する方法及び組成物
NO315545B1 (no) Blanding med bestemt dose, av en angiotensinkonverterende enzyminhibitor ogav en kalsiumkanal antagonist, fremgangsmåte for fremstilling oganvendelse derav ved behandling av kardiovaskul¶re sykdommer
JPH05229944A (ja) モノアミノオキシダーゼｂ阻害因子
TW200906406A (en) Use of a compound that is a neurokinin A NK2 receptor antagonist for the preparation of medicaments for use in the prevention and treatment of sexual dysfunctions
MXPA06003273A (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
HK1051140B (en) Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation
MXPA06008113A (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
JPS6148482B2 (de)
JP2011510994A (ja) 末梢動脈疾患の治療のためのｐｄｅ３阻害剤の増減投与方法